NCT06962865
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Recruiting · Phase 2 · RemeGen Co., Ltd. · registry updated 2025-07-16
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Inclusion
- Voluntarily participate in the study and signed the ICF;
- Male or female, aged 18-75 years;
- All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/IIIC )or recurrent metastatic NSCLC (stage IV ) and not amendable to curative surgery or radiation as assessed by investigator;
- For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy;
- Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;
- Ability to provide at least 6 sections of tumor tissue specimens for staining and testing；
Exclusion
- Subjects with the presence of meningeal metastases, spinal cord compression, or active brain metastases；
- Received ADC or MET inhibitors；
- Suffering from refractory nausea and vomiting, chronic gastrointestinal disorders, inability to swallow pharmaceutical preparations, or previous major bowel resection that may prevent adequate absorption, distribution, metabolism, or excretion of oral medications;
- Subjects with uncontrolled tumor-related pain；
- Use of an investigational drug or major surgery within 4 weeks before the first dose;
- Received any live vaccine within 28 days prior to the first dose or plan to be vaccinated during the study;